- Poster #5915: Three-dimensional (3-D) Multiplex Imaging of Biomarkers in Tumor Tissue
(posted: Apr, 2017)
Clearlight presented research data at the 2017 American Association for Cancer Research (AACR) annual meeting. Includes a link to the poster with the full presentation.
- ClearLight Presents Data on the Multiplex 3D Imaging of the Tumor Microenvironment
(posted: Mar, 2017)
ClearLight announced today that it will present data at the 2017 American Association for Cancer Research meeting in Washington DC on Wednesday, April 5, 2017, 8:00 AM-12:00 PM in the Convention Center Halls A-C, poster session 43, board number 27.
- ClearLight Diagnostics Raises $3.5M in Series B Funding
(posted: Dec, 2016)
Clearlight has completed a $3.5M Series B financing round. The financing will go towards the continued technology platform and applications development using the CLARITY technology and deep imaging with COLM Light Sheet Microscopy.
ClearLight Diagnostics Licenses Intellectual Property Rights from Stanford University for Tissue Processing and Imaging Technologies CLARITY and COLM
posted: October 1st, 2015
SUNNYVALE, Calif., Sept. 15, 2015
ClearLight Diagnostics, a developer of new tools and technologies for the analysis and imaging of tissue samples, announced today that it has signed an exclusive, worldwide license agreement with Stanford University for the intellectual property rights covering inventions relating to tissue processing and imaging. The licensed technologies involve CLARITY, a tissue "clarification" method that renders the tissue optically transparent, and COLM (CLARITY Optimized Light-sheet Microscopy), a new optics system for accelerating image collection from clarified samples. ClearLight is initially funded by a syndicate created by Wiegers Capital Partners LLC, and plans to commercialize products and services based on the licensed technologies.
"We are excited by the prospect of further developing the CLARITY and COLM technologies," said Sarah McCurdy, Chief Executive Officer of ClearLight Diagnostics. "Our development efforts will ultimately impact the lives of many patients through the creation of new tools and services for diagnosing diseases and finding new treatments."
About ClearLight Diagnostics
ClearLight Diagnostics is a technology development company focused on the discovery, development and commercialization of innovative technologies to significantly improve the diagnosis and treatment of a wide range of diseases. The company is developing a groundbreaking tissue processing and imaging platform that allows for the three-dimensional investigation of molecular and structural information within specific tissues. The CLARITY method is built on sophisticated chemical treatments of tissues to make them fully transparent and includes COLM, a powerful imaging platform that allows for visualization of labeled tissue elements, cells and connections within tissue blocks.
For immediate release: Clearlight Diagnostics, LLC.